Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

Core Insights - Apogee Therapeutics, Inc. is set to report interim results from its Phase 1b trial of APG777 for mild-to-moderate asthma on January 6, 2026, followed by a conference call and webcast at 8:00 a.m. ET [1] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized, novel biologics for the inflammatory and immunology (I&I) markets, including treatments for atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications [3] - The company's lead program, APG777, targets the treatment of AD, which is identified as the largest and least penetrated market within the I&I sector [3] - Apogee's antibody programs aim to address the limitations of existing therapies by utilizing established mechanisms of action and advanced antibody engineering to enhance properties such as half-life [3] - The company has four validated targets in its portfolio and is pursuing best-in-class efficacy and dosing through both monotherapies and combinations of its novel antibodies [3]